Arcellx (ACLX) said Sunday preliminary data from a phase 2 trial of anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma demonstrated a 97% overall response rate.
Results from the trial at median follow-up of 9.5 months also showed a complete response/stringent complete response rate of 62% with no delayed neurotoxicities, the company said.
Meanwhile, the median progression-free survival and overall survival were not reached, Arcellx said, adding that three deaths "occurred due to treatment-emergent adverse events."
Multiple myeloma is a type of hematological cancer that can cause bone lesions, loss of bone density and bone fractures, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。